AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12017304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators (PSK and OK-432)
Number of subjects: 0
Study 12017304 — intervention group
Group type: COMPARATOR
Intervention: Post-operative adjuvant chemotherapy or immunochemotherapy
Number of subjects: 0
Study 9718288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 40 mg
Number of subjects: 0
Study 9718288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 80 mg
Number of subjects: 0
Study 9718288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine fumarate 160 mg
Number of subjects: 0
Study 9718288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7917540 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2/week) plus interferon-alpha 2b (6 U/m2 3 times per week)
Number of subjects: 60
Study 7917540 — intervention group
Group type: COMPARATOR
Intervention: vindesine alone
Number of subjects: 60
Study 7917540 — intervention group
Group type: COMPARATOR
Intervention: interferon-alpha 2b alone
Number of subjects: 60
Study 2523921 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol (S)
Number of subjects: 11
Study 2523921 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms of ipratropium (I)
Number of subjects: 11
Study 2523921 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of cromoglycate (C)
Number of subjects: 11
Study 909566 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulated group
Number of subjects: 4
Study 909566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 7034470 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 10 mg twice daily
Number of subjects: 44
Study 7034470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7034470 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 5 mg
Number of subjects: 44
Study 7034470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 44
Study 30483852 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h catheterisation protocol
Number of subjects: 79
Study 30483852 — intervention group
Group type: COMPARATOR
Intervention: 48-h catheterisation protocol
Number of subjects: 79
Study 28322662 — intervention group
Group type: EXPERIMENTAL
Intervention: Think Clearly About Depression online depression self‐management program
Number of subjects: 47
Study 28322662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 27310952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 106
Study 27310952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 25419454 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic TENS
Number of subjects: 40
Study 25419454 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 40
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: CABGa (n = 6)
Number of subjects: 42
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: CABGma (n = 27)
Number of subjects: 42
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: CABGmr (n = 9)
Number of subjects: 42
Study 22495092 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 42
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (CABGa)
Number of subjects: 42
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (CABGma)
Number of subjects: 42
Study 22495092 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (CABGmr)
Number of subjects: 42
Study 20009091 — intervention group
Group type: EXPERIMENTAL
Intervention: Active care management with home telemonitoring (ACM+HT group)
Number of subjects: 150
Study 20009091 — intervention group
Group type: COMPARATOR
Intervention: Monthly care coordination telephone call (CC group)
Number of subjects: 150
Study 18604680 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (Arcoxia)
Number of subjects: 25
Study 18604680 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (Ponstan)
Number of subjects: 25
Study 16037156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum capsules 1.5 g daily for 4 weeks
Number of subjects: 40
Study 16037156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12739921 — intervention group
Group type: EXPERIMENTAL
Intervention: New teaching method for VAS
Number of subjects: 106
Study 12739921 — intervention group
Group type: COMPARATOR
Intervention: Previous teaching method for VAS
Number of subjects: 106
Study 10687910 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐mg increments of midazolam at 1‐min intervals
Number of subjects: 32
Study 10687910 — intervention group
Group type: COMPARATOR
Intervention: 0.1‐mg increments of midazolam without a lock‐out interval
Number of subjects: 32
Study 8558744 — intervention group
Group type: EXPERIMENTAL
Intervention: rUK 4000 IU/min
Number of subjects: 213
Study 8558744 — intervention group
Group type: EXPERIMENTAL
Intervention: rUK 2000 IU/min
Number of subjects: 213
Study 8558744 — intervention group
Group type: EXPERIMENTAL
Intervention: rUK 6000 IU/min
Number of subjects: 213
Study 8558744 — intervention group
Group type: COMPARATOR
Intervention: surgery
Number of subjects: 213
Study 1725892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicardipine (3 x 30 mg)
Number of subjects: 25
Study 1725892 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25
Study 6351585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground lentils
Number of subjects: 6
Study 6351585 — intervention group
Group type: COMPARATOR
Intervention: Whole lentils
Number of subjects: 6
Study 31610637 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight via 12 ounces of coffee)
Number of subjects: 0
Study 31610637 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 0
Study 29624720 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME Plus intervention group (cooking and nutrition education sessions, goal-setting activities, motivational interviewing telephone calls)
Number of subjects: 160
Study 27618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the facet joint capsule
Number of subjects: 120
Study 27618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous denervation of the medial dorsal branch
Number of subjects: 120
Study 27618781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiofrequency lesioning)
Number of subjects: 120
Study 24092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorgan ultrasonography
Number of subjects: 357
Study 24092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Number of subjects: 357
Study 24092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart ultrasonography
Number of subjects: 357
Study 24092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein ultrasonography
Number of subjects: 357
Study 24092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorgan ultrasonography negative for PE
Number of subjects: 357
Study 22331346 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low saturated fat dietary counseling
Number of subjects: 1062
Study 22331346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study 20591628 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1000 mg/day for 14 weeks
Number of subjects: 56
Study 20591628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 weeks
Number of subjects: 56
Study 17266067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR), 8-week intervention, 2.5-hour sessions weekly, led by a licensed clinical psychologist.
Number of subjects: 91
Study 17266067 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group, n = 40.
Number of subjects: 91
Study 16102151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led support and education programme (attended 5-6 times over six months)
Number of subjects: 100
Study 16102151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led support and education programme (attended fewer times)
Number of subjects: 100
Study 16102151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 12764515 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (60 mg/kg per day for three consecutive days)
Number of subjects: 106
Study 12764515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine (two daily doses of 10 mg/kg)
Number of subjects: 106
Study 12764515 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 106
Study 10600424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ascorbic acid supplementation per day
Number of subjects: 75
Study 10600424 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of ascorbic acid supplementation per day
Number of subjects: 75
Study 10600424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8763515 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (100 mg over 3 hours)
Number of subjects: 103
Study 8763515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 1663571 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (Oestrogel)
Number of subjects: 63
Study 1663571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin)
Number of subjects: 63
Study 1663571 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized oral progesterone
Number of subjects: 63
Study 7027873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bromhexine, 32 mg/day
Number of subjects: 30
Study 7027873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30326960 — intervention group
Group type: EXPERIMENTAL
Intervention: ThrIVe-B intervention plus treatment as usual
Number of subjects: 48
Study 30326960 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 48
Study 27209622 — intervention group
Group type: EXPERIMENTAL
Intervention: Total AV
Number of subjects: 40
Study 27209622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphyseal AV
Number of subjects: 40
Study 27209622 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal AV
Number of subjects: 40
Study 24452943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with optimal mineral-content diet (diet group, 27 subjects)
Number of subjects: 45
Study 24452943 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment without dietary change (control group, 18 subjects)
Number of subjects: 45
Study 24452943 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antihypertensive treatment
Number of subjects: 45
Study 22415208 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ program
Number of subjects: 121
Study 22415208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 20182039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) measurement by PET under baseline conditions
Number of subjects: 27
Study 20182039 — intervention group
Group type: COMPARATOR
Intervention: Anti-hypertensive treatment
Number of subjects: 27
Study 18681100 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly strength training over 2 years
Number of subjects: 80
Study 15912037 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III residents (PGY >/= 4) for open repairs
Number of subjects: 1983
Study 15912037 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III residents (PGY >/= 4) for laparoscopic repairs
Number of subjects: 1983
Study 15912037 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II residents (PGY 3) for laparoscopic repairs
Number of subjects: 1983
Study 15912037 — intervention group
Group type: COMPARATOR
Intervention: All groups for laparoscopic repairs
Number of subjects: 1983
Study 15912037 — intervention group
Group type: COMPARATOR
Intervention: All groups for both repairs
Number of subjects: 1983
Study 12420654 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 0
Study 12420654 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 0
Study 10526808 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiology Consultant Report (ACR)
Number of subjects: 371
Study 10526808 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge instructions
Number of subjects: 371
Study 8717556 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg aspirin daily
Number of subjects: 51
Study 8717556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1952169 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with postoperative epidural analgesia (GEN‐EPI)
Number of subjects: 80
Study 1952169 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with on‐demand narcotic analgesia (GEN)
Number of subjects: 80
Study 1952169 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 patients without atherosclerotic vascular disease)
Number of subjects: 80
Study 6174346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60
Study 6174346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30256662 — intervention group
Group type: EXPERIMENTAL
Intervention: HMD (head-mounted display)
Number of subjects: 44
Study 30256662 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone VR
Number of subjects: 44
Study 27894037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysregulation profiles
Number of subjects: 433
Study 27894037 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing profile
Number of subjects: 433
Study 24791969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/kg
Number of subjects: 100
Study 24791969 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.15 ml/kg (Control Group C)
Number of subjects: 100
Study 23261045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose (HD) trivalent inactivated influenza vaccine (60μg of hemagglutinin per strain)
Number of subjects: 9172
Study 23261045 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) trivalent inactivated influenza vaccine (15μg of hemagglutinin per strain)
Number of subjects: 9172
Study 23261045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose (HD) trivalent inactivated influenza vaccine
Number of subjects: 9172
Study 23261045 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) trivalent inactivated influenza vaccine
Number of subjects: 9172
Study 20880602 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid therapy (ALA)
Number of subjects: 0
Study 20880602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19436660 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine use (MU)
Number of subjects: 82
Study 19436660 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 82
Study 19436660 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-married status (combined never married or divorced/separated)
Number of subjects: 82
Study 16428564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal epidural (CSE) technique
Number of subjects: 30
Study 16428564 — intervention group
Group type: COMPARATOR
Intervention: Single-shot spinal (SSS) technique
Number of subjects: 30
Study 15146341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy in the early (prepsychotic) prodromal state
Number of subjects: 0
Study 15146341 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride treatment in the late prodromal (early psychotic) state
Number of subjects: 0
Study 15146341 — intervention group
Group type: COMPARATOR
Intervention: Normal clinical treatment
Number of subjects: 0
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast flush as needed and nonwaste blood sampling
Number of subjects: 174
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast flush as needed and waste blood sampling
Number of subjects: 174
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast flush every 4 hours and waste blood sampling
Number of subjects: 174
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast flush every 4 hours and nonwaste blood sampling
Number of subjects: 174
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion sites 3 cm or higher above the radiocarpal joint
Number of subjects: 174
Study 11244667 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 174
Study 9165136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy (310 patients)
Number of subjects: 501
Study 9165136 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy (191 patients)
Number of subjects: 501
Study 9165136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy for moderately and well-differentiated tumors
Number of subjects: 501
Study 9165136 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy for moderately and well-differentiated tumors
Number of subjects: 501
Study 9165136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous radiotherapy for poorly differentiated tumors
Number of subjects: 501
Study 9165136 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy for poorly differentiated tumors
Number of subjects: 501
Study 8002537 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Negative Airway Pressure (CNAP)
Number of subjects: 8
Study 8002537 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Extrathoracic Pressure (CPEP)
Number of subjects: 8
Study 2569848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (VEC)
Number of subjects: 40
Study 2569848 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (Suc)
Number of subjects: 40
Study 2569848 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (Suc) infusion
Number of subjects: 40
Study 4817160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (25 g) in the morning
Number of subjects: 13
Study 4817160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (25 g) in the afternoon
Number of subjects: 13
Study 4817160 — intervention group
Group type: COMPARATOR
Intervention: Control (non‐apprehensive subjects)
Number of subjects: 13
Study 31634193 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gp120 protein vaccine (Vax004 clinical trial)
Number of subjects: 675
Study 31634193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study 31264761 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving HbA1c, cholesterol, and blood pressure targets
Number of subjects: 371
Study 31264761 — intervention group
Group type: COMPARATOR
Intervention: Achieving one target
Number of subjects: 371
Study 31264761 — intervention group
Group type: COMPARATOR
Intervention: Achieving two targets
Number of subjects: 371
Study 31264761 — intervention group
Group type: COMPARATOR
Intervention: Achieving three targets
Number of subjects: 371
Study 31264761 — intervention group
Group type: EXPERIMENTAL
Intervention: All T2D patients achieving all three targets
Number of subjects: 371
Study 25978820 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized drinking feedback (PDF)
Number of subjects: 325
Study 25978820 — intervention group
Group type: COMPARATOR
Intervention: Educational information (EDU)
Number of subjects: 325
Study 23282136 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria infection
Number of subjects: 690
Study 23282136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris co-infection
Number of subjects: 690
Study 21527603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic parenteral nutrition (PN) with DEHP exposure
Number of subjects: 12
Study 21527603 — intervention group
Group type: COMPARATOR
Intervention: Nontreated infants
Number of subjects: 12
Study 18772101 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue combined with mifepristone
Number of subjects: 0
Study 18772101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation and evacuation (D&E)
Number of subjects: 0
Study 18772101 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues administered by non-invasive routes
Number of subjects: 0
Study 16581549 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer treatment
Number of subjects: 780
Study 16581549 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 780
Study 16581549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 780
Study 14627852 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 131I activities
Number of subjects: 218
Study 14627852 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease specific standard values per millilitre of thyroid tissue
Number of subjects: 218
Study 14627852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐therapeutic radioiodine test
Number of subjects: 218
Study 14627852 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h and 48 h test uptake measurements
Number of subjects: 218
Study 11077136 — intervention group
Group type: EXPERIMENTAL
Intervention: Antero-lateral paddle position
Number of subjects: 59
Study 11077136 — intervention group
Group type: COMPARATOR
Intervention: Antero-posterior paddle position
Number of subjects: 59
Study 11077136 — intervention group
Group type: EXPERIMENTAL
Intervention: Antero-lateral followed by antero-posterior shocks
Number of subjects: 59
Study 11077136 — intervention group
Group type: COMPARATOR
Intervention: Antero-posterior followed by antero-lateral shocks
Number of subjects: 59
Study 8839903 — intervention group
Group type: COMPARATOR
Intervention: CEF (cyclophosphamide 600 mg/sqm i.v., epidoxorubicin 60 mg/sqm i.v. and fluorouracil 600 mg/sqm i.v.)
Number of subjects: 258
Study 8839903 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-CEF (diethylstilbestrol 1 mg orally days 1-3, CEF on day 4)
Number of subjects: 258